Back to Home > Business > Press Releases > Press Releases - Biotechnology

Press Releases - Biotechnology   RSS Add to My Yahoo

Top Story

  • Former CMS Administrator: "'Blunt Instrument' Policies an Increasingly Bad Fit in Era of Personalized Health Care"

    Recent legislative emphasis on price negotiation and physician reimbursement as a means to reduce health care costs are nothing more than "short term patches" that hold no potential for truly reforming health care, former Centers for Medicare and Medicaid Services (CMS) Administrator Dr. Mark McClellan told hundreds of health care decision makers today in delivering the keynote address at Medco Health Solutions, Inc. (NYSE: MHS) 2008 Drug Trend "Predictions" Symposium.

MORE STORIES

  • Urologix Launches New CTC Advance Catheter at 2008 American Urological Association Annual Meeting

    Urologix(R), Inc. (NASDAQ:ULGX) announced today it is launching its next generation Cooled ThermoTherapy(TM) (CTT) treatment catheter, CTC Advance(TM) at the 2008 American Urological Association Annual Meeting in Orlando, Florida being held May 17-22, 2008. Urologix is the pioneer of Cooled ThermoTherapy for the treatment of enlarged prostate disease in the comfortable setting of a physician's office.

  • CapMed Executive to Discuss 'Key to Personal Health Record Adoption' at TEPR 2008 Conference

    CapMed, a division of Bio-Imaging Technologies, Inc. (NASDAQ: BITI) and a leader in interactive personal health management solutions, today announced that Mary Ellen Zipper, Director of Client Relations, will educate attendees about the "Key to Personal Health Record Adoption" at this year's TEPR conference in Fort Lauderdale, Florida, on May 20th at 8 a.m. and 2 p.m. in Room 204.

  • Vanguard Urologic Institute First to Implant AxoGen's Avance Nerve Graft Using a Robot for Cavernous Nerve Repair

    In 2007, more than 200,000 men were newly diagnosed with prostate cancer, with many of them undergoing radical prostatectomies. During a radical prostatectomy, care is taken to remove the cancer and the prostate while preserving the surrounding nerves. The cavernous nerves, which lie next to the prostate, are essential for erectile function, and to a lesser degree, urinary continence.

  • Accentia Biopharmaceuticals Reports Fiscal Second Quarter Financial Results

    Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that the Company has filed its Quarterly Report (Form 10-Q) with the SEC, reporting the results of its operations, including consolidated results with its majority-owned subsidiary, Biovest International, Inc. (OTCBB:BVTI), for its second fiscal quarter ended March 31, 2008. The Company also announced that it is scheduled to present at the Jefferies & Co. 2nd Annual Healthcare Conference in New York City.

  • Catalyst Pharmaceutical Partners Reports First Quarter 2008 Financial Results

    Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the quarter ended March 31, 2008. The Company also announced the addition of Frank Greenway, M.D. to Catalyst's Scientific Advisory Board and the retention of Andrew Forman as a Business Development and Investor Relations Consultant.

  • RTI Biologics Announces Successful Implantation of First Fresh-Stored Osteochondral Allograft

    RTI Biologics, Inc. (RTI) (Nasdaq:RTIX), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, announces the successful implantation of its first fresh-stored osteochondral (OC) allograft in Arkansas last Monday.

  • Bioheart, Inc. Announces Financial Results for First Quarter 2008

    Bioheart, Inc. (Nasdaq: BHRT) a biotechnology company that is focused on the development of autologous (patient-derived) cell therapies and devices for the treatment of chronic and acute heart damage, today announced financial results for the quarter ended March 31, 2008.

  • Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute

    Tigris Pharmaceuticals, Inc. announced today the execution of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on clinical and preclinical development of AFP-464, an aminoflavone currently in Phase I development. AFP-464 is converted to metabolites which bind covalently to DNA, resulting in p53 activation and apoptosis.

  • AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting

  • IVAX Diagnostics Reports First Quarter Results

    IVAX Diagnostics, Inc. (AMEX:IVD) reported its financial results for the first quarter of 2008. For the quarter, IVAX Diagnostics recorded net income of $345,000, or earnings of $0.01 per share, compared to net loss of $238,000, or loss of $0.01 per share, in the first quarter of 2007. Net revenues for the first quarter of 2008 were $5,242,000, an increase of $296,000, or 6%, from the first quarter of 2007.

  • Dyadic Announces Mailing of Notice of Annual Stockholders Meeting to Be Held On Friday, June 20, 2008

    Dyadic International, Inc. (the "Company") announced today that, in accordance with the Order of the Delaware Court of Chancery in Emalfarb v. Dyadic International, Inc. (C.A. No. 3353-VCP) previously reported in a Current Report on Form 8-K filed with the SEC on April 15, 2008, on Friday, May 9, 2008, it mailed to its stockholders of record as of the close of business on April 23, 2008 a notice of its annual meeting of stockholders to be held on Friday, June 20, 2008, at 10:00 a.m., EDT, at the Doubletree Hotel, 4431 PGA Boulevard, Palm Beach Gardens, Florida 33410.

  • NeoStem to Expand Stem Cell Collection Center Network to Florida

    NeoStem, Inc. (Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, today announced that a site has been secured for a new stem cell collection center in Coral Gables, Florida, a suburb of Miami.

  • Dawning Technologies, Inc. Releases JavaLin/PDI Portable Device Interface

    Dawning Technologies, Inc. announces the release of their latest small footprint interface device in the new JavaLin/PDI Portable Device Interface. The JavaLin/PDI is the fifth generation of intelligent clinical interfaces from Dawning and provides an unparalleled range of features and capabilities primarily aimed at the connection of clinical instruments to information systems. Combining the power of JResultNet Interface Engine Software, embedded within the JavaLin/PDI, with a flexible hardware design, the JavaLin/PDI supports a variety of industry standard communication protocols and can run any of the applications in Dawning's Java Driver Library, now available for more than 400 instruments.

  • Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research

    The Cancer Research Alliance, an organization comprised of 12 of the nation's best cancer centers including Moffitt Cancer Center, is asking all 303 million Americans to exercise their power over cancer by stepping up and donating $1 to cancer research efforts this Mother's Day through Father's Day.

  • AACE Calls for New Standards for Safer Insulin Pump Use

    "The American Association of Clinical Endocrinologists applauds the FDA's efforts to protect the safety of children and adolescents who are using insulin pumps," said Dr. Richard Hellman, the Association's President.

  • Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session

    Alpharma Inc. (NYSE: ALO), a global specialty pharmaceutical company, today announced results from clinical trials that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) capsules demonstrated clinically relevant features addressing abuse liability alongside a promising safety and efficacy profile. The Phase I and II studies, presented at the 27th Annual Scientific Session of the American Pain Society, examined the effects of ALO-01 when crushed -- a common method of abuse -- among recreational drug users and when taken whole, as intended, by chronic pain patients.

  • Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions

    Alpharma Inc. (NYSE: ALO), a leading global specialty pharmaceutical company, announced today that two studies to be presented this week at the American Pain Society annual meeting demonstrate the efficacy, tolerability and positive pharmacokinetic profile of Alpharma Pharmaceuticals' FLECTOR(R) Patch (diclofenac epolamine topical patch) 1.3%, the first and only prescription anti-inflammatory pain relief patch in the United States. FLECTOR(R) Patch has been available since January in the United States for the topical treatment of acute pain due to minor strains, sprains and contusions.

  • BEMA(TM) Fentanyl Phase III Data Demonstrating Efficacy and Tolerability to be Presented at American Pain Society Annual Meeting

    BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and commercial partner Meda Pharmaceuticals will present today and tomorrow, data from Phase III clinical pivotal trials for BEMA(TM) Fentanyl, a potential treatment for breakthrough pain (BTP) in opioid tolerant patients with cancer. The presentations will be made at the 27th Annual Scientific Meeting of the American Pain Society (APS) in Tampa, Florida.

  • New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain

    Patients treated with lacosamide demonstrated sustained pain relief from diabetic neuropathic pain (DNP), compared to placebo-treated patients, according to data presented at the 27th annual meeting of the American Pain Society (APS) in Tampa, Fla.

Miami Top Jobs

    Quick Job Search

    Enter Keyword(s): Enter City: Select a State: Select a Category: Advanced Job Search Search by Category

     Ad links